CTRI/2018/08/015319已完成2 期
An open randomized trial in pre-diabetes evaluating effectiveness of add-on plant extracts used in homeopathy as mother tinctures
Dept of Higher Education Science Technology and Biotechnology Govt of West Bengal0 个研究点目标入组 82 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age 35-65 yrs
- •2. Both sexes
- •3. Impaired glucose regulation; fasting plasma glucose concentration of 100-125 mg/dL (impaired fasting glucose; IFG) and 2 hrs. post 75 gm glucose load plasma glucose value of 140-199 mg/dL (impaired glucose tolerance; IGT)
- •4. Written consent to participate
排除标准
- •1. Too unwell to take part
- •2. Cases with other systemic unevaluated or uncontrolled diseases or systemic infections affecting quality of life or on other treatment therapies
- •3. Psychiatric illness
- •4. Patients with any vital organ failure
- •5. History of homeopathic treatment for any chronic disease within last 6 months
- •6. Self-reported immune-compromised states
- •7. Alcohol and /or drug addiction or dependence
- •8. Pregnancy and lactation
研究者
相似试验
招募中
1 期
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple MyelomaMultiple myeloma (MM)MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104CTIS2023-503689-21-00F. Hoffmann-La Roche AG135
进行中（未招募）
1 期
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Canceron-small cell lung cancerMedDRA version: 9.1 Level: LLT Classification code 10061873 Term: Non-small cell lung cancerEUCTR2007-005941-39-GBMerck & Co Inc95
进行中（未招募）
不适用
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung CancerEUCTR2007-005941-39-ATMerck Sharp & Dohme GmbH68
进行中（未招募）
1 期
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Canceron-small cell lung cancerMedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-005941-39-DKMerck & Co. Inc.95
进行中（未招募）
不适用
A study comparing MK-0646 with Erlotinib for treatment of one type of lung cancerEUCTR2007-005941-39-SEMerck Sharp & Dohme (Sweden) AB95